• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection.

作者信息

Li Dan, Chu Qingfei, Li Kang, Li Lanjuan, Shao Yiming

机构信息

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.

National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.

出版信息

Signal Transduct Target Ther. 2024 Aug 21;9(1):208. doi: 10.1038/s41392-024-01926-w.

DOI:10.1038/s41392-024-01926-w
PMID:39164256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11335868/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5336/11335868/d081b7010a8d/41392_2024_1926_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5336/11335868/d081b7010a8d/41392_2024_1926_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5336/11335868/d081b7010a8d/41392_2024_1926_Fig1_HTML.jpg

相似文献

1
Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection.在一波大规模的新冠病毒突破性感染后，免疫回忆增强了交叉反应性抗体的持久性。
Signal Transduct Target Ther. 2024 Aug 21;9(1):208. doi: 10.1038/s41392-024-01926-w.
2
SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients.突破阶段老年患者的 SARS-CoV-2 刺突 IgG 抗体和 ACE2 受体结合抑制水平。
Microbiol Spectr. 2022 Dec 21;10(6):e0274722. doi: 10.1128/spectrum.02747-22. Epub 2022 Nov 21.
3
Dominant and cross-reactive S1-specific memory B cell response induced by primary SARS-CoV-2 infection.初次感染新型冠状病毒（SARS-CoV-2）诱导产生的显性和交叉反应性S1特异性记忆B细胞应答。
Sci Rep. 2025 Jul 1;15(1):20591. doi: 10.1038/s41598-025-06847-4.
4
Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.原型和 BA.5 蛋白纳米颗粒疫苗可预防叙利亚仓鼠感染奥密克戎 BA.5 变异株。
J Virol. 2024 Mar 19;98(3):e0120623. doi: 10.1128/jvi.01206-23. Epub 2024 Feb 2.
5
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.新冠病毒感染 14 个月后 COVID-19 恢复期患者结合抗体和中和抗体的动态分析。
Front Immunol. 2021 Nov 26;12:793953. doi: 10.3389/fimmu.2021.793953. eCollection 2021.
6
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.SARS-CoV-2 BA.4/5 感染在混合免疫背景下比 BA.1 引发更多的交叉反应性 FcγRIIIa 信号传导和中和作用。
J Virol. 2024 Jul 23;98(7):e0067824. doi: 10.1128/jvi.00678-24. Epub 2024 Jul 2.
7
Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.检测血清交叉反应抗体和对 SARS-CoV-2 的记忆反应在大流行前和 COVID-19 后恢复期样本中。
J Infect Dis. 2021 Oct 28;224(8):1305-1315. doi: 10.1093/infdis/jiab333.
8
XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies.XBB.1.5单价疫苗可诱导对SARS-CoV-2变体（如HV.1和JN.1）以及SARS-CoV-1产生持久的交叉反应，但产生的XBB.1.5特异性抗体有限。
mBio. 2025 Apr 9;16(4):e0360724. doi: 10.1128/mbio.03607-24. Epub 2025 Mar 5.
9
Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.针对 SARS-CoV-2 的预先存在的体液交叉反应性免疫的证据和影响。
Immun Inflamm Dis. 2021 Mar;9(1):128-133. doi: 10.1002/iid3.367. Epub 2020 Dec 15.
10
Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets.SARS-CoV-2 感染后 B 细胞免疫优势分析揭示了针对非中和性病毒靶点的抗体进化。
Immunity. 2021 Jun 8;54(6):1290-1303.e7. doi: 10.1016/j.immuni.2021.05.001. Epub 2021 May 6.

引用本文的文献

1
Mechanistic insights and nanomedicine innovations of oligomeric proanthocyanidin in precision oncology: Ablating self-renewal capacity of metastatic cancer stem cells via multi-pathway modulation.原花青素低聚物在精准肿瘤学中的作用机制及纳米医学创新：通过多途径调控消除转移性癌症干细胞的自我更新能力
Med Oncol. 2025 Sep 10;42(11):467. doi: 10.1007/s12032-025-02992-y.
2
Efficient boosting of Omicron-reactive memory B cells after breakthrough infection protects from repeated exposure.突破性感染后对奥密克戎反应性记忆B细胞的有效增强可预防再次感染。
iScience. 2025 Mar 25;28(4):112278. doi: 10.1016/j.isci.2025.112278. eCollection 2025 Apr 18.

本文引用的文献

1
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022.COVID-19 疫苗对成年人感染、住院和死亡的长期有效性：截至 2022 年 12 月快速实时系统证据综合和荟萃分析的结果。
Lancet Respir Med. 2023 May;11(5):439-452. doi: 10.1016/S2213-2600(23)00015-2. Epub 2023 Feb 10.
2
Modeling transmission of SARS-CoV-2 Omicron in China.模拟 SARS-CoV-2 奥密克戎在中国的传播。
Nat Med. 2022 Jul;28(7):1468-1475. doi: 10.1038/s41591-022-01855-7. Epub 2022 May 10.
3
COVID-19 vaccine breakthrough infections.
COVID-19 疫苗突破性感染。
Science. 2021 Dec 24;374(6575):1561-1562. doi: 10.1126/science.abl8487. Epub 2021 Dec 23.
4
Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.美国五家退伍军人事务医疗中心 2021 年 2 月 1 日至 9 月 30 日期间住院退伍军人中 Moderna 和辉瑞-BioNTech COVID-19 疫苗的有效性和抗体反应比较。
MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1700-1705. doi: 10.15585/mmwr.mm7049a2.
5
Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.针对 SARS-CoV-2 的预先存在的体液交叉反应性免疫的证据和影响。
Immun Inflamm Dis. 2021 Mar;9(1):128-133. doi: 10.1002/iid3.367. Epub 2020 Dec 15.